I. El‐Hariry

Frank Pétavy, Jean-Pascal Machiels, Patrick Schöffski, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials

K. Ang, K. Harrington, C. Woodman, 2016, Head & neck.

A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).

C. Tournigand, R. Guimbaud, Anu Gupta, 2017 .

Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps.

I. El-Hariry, M. Pignatelli, A. Karayiannakis, 1997, The American journal of pathology.

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

K. Harrington, M. Housset, É. Remenár, 2013, European journal of cancer.

Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood

D. Proia, J. Trepel, Kennichi C. Dowdell, 2017, Leukemia & lymphoma.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer

M. Socinski, Kwok-Kin Wong, L. Sequist, 2013 .

Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer.

I. El-Hariry, M. Pignatelli, I. El‐Hariry, 1997, Expert opinion on investigational drugs.

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

J. Bourhis, K. Harrington, G. Manikhas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013, Clinical Cancer Research.

Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

A. Ravaud, J. Machiels, C. Sternberg, 2010, European journal of cancer.

Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).

A. Ravaud, J. Machiels, H. von der Maase, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

D. Lacombe, J. Bogaerts, J. Langendijk, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

R. Herings, M. Janssen-Heijnen, I. El-Hariry, 2012, Head & neck.

Cancer Therapy : Preclinical Preclinical Activity Pro fi le and Therapeutic Ef fi cacy of the HSP 90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013 .

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

P Sebastian, K. Harrington, C. Nutting, 2011, British Journal of Cancer.

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

W. Guo, L. Rosen, M. Karol, 2013, BMC Cancer.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

S. Chandarlapaty, D. Lake, C. Hudis, 2014, Clinical breast cancer.

FIBROBLAST GROWTH FACTOR 1 AND FIBROBLAST GROWTH FACTOR 2 IMMUNOREACTIVITY IN GASTROINTESTINAL TUMOURS

N. Lemoine, I. El-Hariry, M. Pignatelli, 1997, The Journal of pathology.

A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck

Martin O. Leach, David J. Collins, Brandon Whitcher, 2011, Magnetic Resonance Materials in Physics, Biology and Medicine.

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors

N. Spector, S. Bacus, I. El-Hariry, 2007, Breast Cancer Research.

FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines

N. Lemoine, N. Lemoine, M. Pignatelli, 2001, British Journal of Cancer.

Characterization of the E‐cadherin–catenin complexes in pancreatic carcinoma cell lines

N. Lemoine, I. El-Hariry, M. Pignatelli, 1999, The Journal of pathology.

Head and neck cancer in South East England between 1995-1999 and 2000-2004: An estimation of incidence and distribution by site, stage and histological type.

H. Møller, J. Tyczynski, K. Linklater, 2009, Oral oncology.

Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells

I. El-Hariry, M. Pignatelli, J. Calam, 1999, Gut.

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

J. Bruix, J. Llovet, P. Ruff, 2001, European journal of cancer.

Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

D. Proia, Jing Wen, G. Nagaraju, 2013, Angiogenesis.

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

O. Bouché, L. Mineur, J. Metges, 2022, Journal of Clinical Oncology.

Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC

A. Antonov, S. Ramalingam, D. Fennell, 2014 .

Expression of E-Cadherin-Associated Molecules (a-, f3-, and y-Catenins and p120) in Colorectal Polyps

I. El-Hariry, Alireza Valizadeh, M. Pignatelli, 2007 .

A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

J. Machiels, D. Richel, M. Groot, 2005 .

Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.

J. Bourhis, K. Harrington, C. Nutting, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGF‐1 and FGF‐2 regulate the expression of E‐cadherin and catenins in pancreatic adenocarcinoma

N. Lemoine, I. El-Hariry, M. Pignatelli, 2001, International journal of cancer.